Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
Wall Street analysts are divided in their predictions for Stryker stock's future performance. The Michigan-based medical technology company, with a market cap of $127.1 billion, has underperformed relative to the broader market, declining 12.8% compared to the S&P 500's 20.2% gain. While analysts maintain a strong buy consensus, concerns over slowing organic growth and softer sales momentum have weighed on the stock.
Despite a 9.4% revenue increase in Q2 and a 5.8% earnings beat, many analysts believe Stryker's top line remains a warning sign of potential demand slowdown. However, recent positive developments, such as a $100 million contract modification for Stryker Sales unit from the U.S. Defense Logistics Agency, have provided investors with a boost.
Analysts expect Stryker's EPS to grow 10.2% to $15.02 for the fiscal year 2026, with a price target averaging $379.81, representing a 11.7% premium to the current stock price.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.